Figure 1 Key mechanistic pathways involved in the gut–liver axis in NAFLD progression Figure 1 | Key mechanistic pathways involved in the gut–liver axis.

Slides:

Advertisements

Similar presentations

Regulation of Adipocyte Lipolysis

Advertisements

Long-term Complications of Type 2 Diabetes

Lipoprotein Metabolism And Disorders

LIPOPROTEIN METABOLISM

H 3 CCCCCCCCCCCCCCC COO H 3 CCCCCCCCCCCCCCC COO H 3 CCCCCCCCCCCCCCC COO H 3 CCCCCCCCCCCCCCC.

Recent Advances in understanding Alcoholic Liver Disease

The Role of Gut Microbiota in Non-alcoholic Fatty Liver Disease

The Endocrine Pancreas

Obesity and the Microbiota

Figure 2 Inflammatory pathways affecting hepatic insulin resistance

Figure 4 Intestinal lacteal absorption and immune cell trafficking

Figure 1 Differential immune responses in the gut (oral tolerance)

Figure 5 Dendritic cells in liver inflammation

Pathways of liver injury in alcoholic liver disease

Role of Lipotoxicity and Gut-Liver Axis in NASH Pathogenesis

Figure 1 Contribution of the gut microbiota

Figure 3 The fat–intestine–kidney axis

Figure 1 Pathophysiological aspects of insulin

Volume 47, Issue 1, Pages (July 2007)

Figure 1 Immune mechanisms in liver homeostasis

Figure 2 Signalling molecules and pathways involved in HSC activation

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 The sensory and secretory function of the L cell

Figure 3 Candidate signalling pathways of irisin in hepatocytes

Figure 2 Mechanisms of the gut–autonomic

Gut microbiota and non-alcoholic fatty liver disease: new insights

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Gut Microbes Make for Fattier Fish

Figure 3 Polysaccharides from plants and mushrooms

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Advanced Nutrition Lipids 5 MargiAnne Isaia, MD MPH.

Figure 1 An overview of the TIMER microbiota–host

Figure 3 The mechanism of injury in ACLF

Fishing Out a Sensor for Anti-inflammatory Oils

Figure 2 Organ crosstalk in the pathophysiology

Figure 4 Macrophages in liver inflammation

The Intestinal Immune System in Obesity and Insulin Resistance

Signalling pathways in alcohol-induced liver inflammation

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Figure 2 Pro-inflammatory and anti-inflammatory effects of the gut microbiota Figure 2 | Pro-inflammatory and anti-inflammatory effects of the gut microbiota.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Innate lymphoid cells in liver inflammation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Pathways in Microbe-Induced Obesity

Pathways of liver injury in alcoholic liver disease

The Origins and Drivers of Insulin Resistance

Nat. Rev. Rheumatol. doi: /nrrheum

Gut Microbiota and Its Possible Relationship With Obesity

Figure 2 Microbiota-related pathways in atherosclerosis

Figure 2 The hypoxia-induced proinflammatory

Figure 4 Role of exosomes in the pathogenesis of alcoholic hepatitis

Chengcheng Jin, Jorge Henao-Mejia, Richard A. Flavell Cell Metabolism

The genetics of alcohol dependence and alcohol-related liver disease

Figure 2 Lipid metabolism and metabolism-disrupting chemicals.

Obesity and the Microbiota

Figure 1 The major pathways of lipid metabolism

Gut Microbes Make for Fattier Fish

Circulating FFAs: origins and lipotoxic effects.

Figure 1 NAFLD pathogenesis

Figure 2 Initiators of obesity-associated inflammation in adipocytes

Knockdown of MPST weakens JNK phosphorylation, ameliorates hepatic oxidative stress and suppresses the release of MCP-1. Knockdown of MPST weakens JNK.

Adel Hammoutene, Pierre-Emmanuel Rautou Journal of Hepatology

Sander Lefere, Frank Tacke JHEP Reports

The Endocrine Pancreas

Figure 1 Thyroid hormone effects on hepatic lipid metabolism

Presentation transcript:

Figure 1 Key mechanistic pathways involved in the gut–liver axis in NAFLD progression Figure 1 | Key mechanistic pathways involved in the gut–liver axis in NAFLD progression. (1) Short-chain fatty acids (SCFAs) have effects on G-protein coupled receptors GPR41 and GPR43, causing release of peptide YY (PYY) and glucagon-like peptide 1 (GLP-1), respectively, from neuroendocrine L cells. Increased energy delivery in the form of SCFAs also inhibits adenosine monophosphate activated protein kinase (AMPK) in the liver, which increases hepatic free fatty acid (FFA) accumulation via decreased β-oxidation. (2) Dysbiosis inhibits secretion of fasting induced adipose factor (FIAF, also known as angiopoietin-related protein 4), which in turn inhibits endothelial lipoprotein lipase (LPL), which is responsible for releasing triglycerides from circulating chylomicrons and VLDL. Decreased circulating FIAF levels result in transactivation of hepatic lipogenic enzymes by carbohydrate-responsive element-binding protein (ChREBP) and sterol regulatory element-binding protein 1c (SREBP-1c). The net effect is increased triglyceride storage in adipocytes and liver. (3) Lipopolysaccharide (LPS) stimulates Toll-like receptor 4 (TLR4) on endothelial cells and TLR9 on dendritic cells. This activation induces inflammasomes and pro-inflammatory cytokines, which induce NAFLD progression. LPS also has direct effects on Kupffer cells and hepatic stellate cells to drive steatohepatitis to fibrosis. (4) Dysbiosis can also result in increased endogenous alcohol production, which increases intestinal permeability with disruption of tight junctions (zona occludins), allowing endotoxins and ethanol to have direct effects on the liver. (5) The intestinal microbiota converts dietary phosphatidylcholine (PDC) to choline and to hepatotoxic trimethylamine (TMA). Reduced availability of dietary choline inhibits VLDL excretion from the liver inducing steatosis. Leung, C. et al. (2016) The role of the gut microbiota in NAFLD Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.85